The effects of LY2405319, an FGF21 Analog, in obese human subjects with type 2 diabetes

Cell Metabolism

Volumn 18, Issue 3, 2013, Pages 333-340

  Gaich, Gregory ^a   Chien, Jenny Y ^a   Fu, Haoda ^a   Glass, Leonard C ^a   Deeg, Mark A ^a   Holland, William L ^b   Kharitonenkov, Alexei ^a   Bumol, Thomas ^a   Schilske, Holger K ^a   Moller, David E ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ADIPONECTIN; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CORTICOSTEROID; DRUG ANTIBODY; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LY 2405319; METFORMIN; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEADACHE; HUMAN; HYPERSENSITIVITY; INJECTION SITE REACTION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URTICARIA;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN; MALE; MIDDLE AGED; OBESITY; PLACEBO EFFECT; TRIGLYCERIDES; YOUNG ADULT;

EID: 84883481988     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2013.08.005     Document Type: Article

References (40)

1. A.C. Adams, C.C. Cheng, T. Coskun, and A. Kharitonenkov FGF21 requires βklotho to act in vivo PLoS ONE 7 2012 e49977
2. A.C. Adams, T. Coskun, A.R. Rovira, M.A. Schneider, D.W. Raches, R. Micanovic, H.A. Bina, J.D. Dunbar, and A. Kharitonenkov Fundamentals of FGF19 & FGF21 action in vitro and in vivo PLoS ONE 7 2012 e38438
3. A.C. Adams, C.A. Halstead, B.C. Hansen, A.R. Irizarry, J.A. Martin, S.R. Myers, V.L. Reynolds, H.W. Smith, V.J. Wroblewski, and A. Kharitonenkov LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys PLoS ONE 8 2013 e65763
4. A.C. Adams, C. Yang, T. Coskun, C.C. Cheng, R.E. Gimeno, Y. Luo, and A. Kharitonenkov The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue Mol Metab. 2 2013 31 37
5. B. Angelin, T.E. Larsson, and M. Rudling Circulating fibroblast growth factors as metabolic regulators - a critical appraisal Cell Metab. 16 2012 693 705
6. M.K. Badman, A. Koester, J.S. Flier, A. Kharitonenkov, and E. Maratos-Flier Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis Endocrinology 150 2009 4931 4940
7. A.H. Berg, T.P. Combs, X. Du, M. Brownlee, and P.E. Scherer The adipocyte-secreted protein Acrp30 enhances hepatic insulin action Nat. Med. 7 2001 947 953
8. E.D. Berglund, C.Y. Li, H.A. Bina, S.E. Lynes, M.D. Michael, A.B. Shanafelt, A. Kharitonenkov, and D.H. Wasserman Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity Endocrinology 150 2009 4084 4093
9. A.O. Chavez, M. Molina-Carrion, M.A. Abdul-Ghani, F. Folli, R.A. Defronzo, and D. Tripathy Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance Diabetes Care 32 2009 1542 1546
10. W.W. Chen, L. Li, G.Y. Yang, K. Li, X.Y. Qi, W. Zhu, Y. Tang, H. Liu, and G. Boden Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus Exp. Clin. Endocrinol. Diabetes 116 2008 65 68
11. T. Coskun, H.A. Bina, M.A. Schneider, J.D. Dunbar, C.C. Hu, Y. Chen, D.E. Moller, and A. Kharitonenkov Fibroblast growth factor 21 corrects obesity in mice Endocrinology 149 2008 6018 6027
12. A.W. Drong, C.M. Lindgren, and M.I. McCarthy The genetic and epigenetic basis of type 2 diabetes and obesity Clin. Pharmacol. Ther. 92 2012 707 715
13. J. Dushay, P.C. Chui, G.S. Gopalakrishnan, M. Varela-Rey, M. Crawley, F.M. Fisher, M.K. Badman, M.L. Martinez-Chantar, and E. Maratos-Flier Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease Gastroenterology 139 2010 456 463
14. F.M. Fisher, S. Kleiner, N. Douris, E.C. Fox, R.J. Mepani, F. Verdeguer, J. Wu, A. Kharitonenkov, J.S. Flier, E. Maratos-Flier, and B.M. Spiegelman FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis Genes Dev. 26 2012 271 281
15. I.N. Foltz, S. Hu, C. King, X. Wu, C. Yang, W. Wang, J. Weiszmann, J. Stevens, J.S. Chen, and N. Nuanmanee Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex Sci. Transl. Med. 4 2012 ra153
16. C. Gälman, T. Lundåsen, A. Kharitonenkov, H.A. Bina, M. Eriksson, I. Hafström, M. Dahlin, P. Amark, B. Angelin, and M. Rudling The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man Cell Metab. 8 2008 169 174
17. C. Hale, M.M. Chen, S. Stanislaus, N. Chinookoswong, T. Hager, M. Wang, M.M. Véniant, and J. Xu Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance Endocrinology 153 2012 69 80
18. R. Hecht, Y.S. Li, J. Sun, E. Belouski, M. Hall, T. Hager, J. Yie, W. Wang, D. Winters, and S. Smith Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of Type 2 diabetes PLoS ONE 7 2012 e49345
19. W.L. Holland, A.C. Adams, J.T. Brozinick, H.H. Bui, Y. Miyauchi, C.M. Kusminski, S.M. Bauer, M. Wade, E. Singhal, and C.C. Cheng An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice Cell Metab. 17 2013 790 797
20. Y. Hotta, H. Nakamura, M. Konishi, Y. Murata, H. Takagi, S. Matsumura, K. Inoue, T. Fushiki, and N. Itoh Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver Endocrinology 150 2009 4625 4633
21. T. Inagaki, V.Y. Lin, R. Goetz, M. Mohammadi, D.J. Mangelsdorf, and S.A. Kliewer Inhibition of growth hormone signaling by the fasting-induced hormone FGF21 Cell Metab. 8 2008 77 83
22. A. Kharitonenkov, J.M. Beals, R. Micanovic, B.A. Strifler, R. Rathnachalam, V.J. Wroblewski, S. Li, A. Koester, A.M. Ford, and T. Coskun Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319 PLoS ONE 8 2013 e58575
23. A. Kharitonenkov, T.L. Shiyanova, A. Koester, A.M. Ford, R. Micanovic, E.J. Galbreath, G.E. Sandusky, L.J. Hammond, J.S. Moyers, and R.A. Owens FGF-21 as a novel metabolic regulator J. Clin. Invest. 115 2005 1627 1635
24. A. Kharitonenkov, V.J. Wroblewski, A. Koester, Y.F. Chen, C.K. Clutinger, X.T. Tigno, B.C. Hansen, A.B. Shanafelt, and G.J. Etgen The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Endocrinology 148 2007 774 781
25. S.A. Kliewer, and D.J. Mangelsdorf Fibroblast growth factor 21: from pharmacology to physiology Am. J. Clin. Nutr. 91 2010 254S 257S
26. Z. Lin, H. Tian, K.S. Lam, S. Lin, R.C. Hoo, M. Konishi, N. Itoh, Y. Wang, S.R. Bornstein, A. Xu, and X. Li Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice Cell Metab. 17 2013 779 789
27. D.E. Moller Metabolic disease drug discovery- "hitting the target" is easier said than done Cell Metab. 15 2012 19 24
28. D.E. Moller, and K.D. Kaufman Metabolic syndrome: a clinical and molecular perspective Annu. Rev. Med. 56 2005 45 62
29. J. Mu, J. Pinkstaff, Z. Li, L. Skidmore, N. Li, H. Myler, Q. Dallas-Yang, A.M. Putnam, J. Yao, and S. Bussell FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents Diabetes 61 2012 505 512
30. U.B. Pajvani, M. Hawkins, T.P. Combs, M.W. Rajala, T. Doebber, J.P. Berger, J.A. Wagner, M. Wu, A. Knopps, and A.H. Xiang Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity J. Biol. Chem. 279 2004 12152 12162
31. L.J. Rasmussen-Torvik, C.L. Wassel, J. Ding, J. Carr, M. Cushman, N. Jenny, and M.A. Allison Associations of body mass index and insulin resistance with leptin, adiponectin, and the leptin-to-adiponectin ratio across ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA) Ann. Epidemiol. 22 2012 705 709
32. T. Schraw, Z.V. Wang, N. Halberg, M. Hawkins, and P.E. Scherer Plasma adiponectin complexes have distinct biochemical characteristics Endocrinology 149 2008 2270 2282
33. R. Smith, A. Duguay, J. Weiszmann, S. Stanislaus, E. Belouski, L. Cai, J. Yie, J. Xu, J. Gupte, X. Wu, and Y. Li A novel approach to improve the function of FGF21 BioDrugs 27 2013 159 166
34. A.T. Turer, and P.E. Scherer Adiponectin: mechanistic insights and clinical implications Diabetologia 55 2012 2319 2326
35. M.M. Véniant, R. Komorowski, P. Chen, S. Stanislaus, K. Winters, T. Hager, L. Zhou, R. Wada, R. Hecht, and J. Xu Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys Endocrinology 153 2012 4192 4203
36. W. Wei, P.A. Dutchak, X. Wang, X. Ding, X. Wang, A.L. Bookout, R. Goetz, M. Mohammadi, R.D. Gerard, and P.C. Dechow Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ Proc. Natl. Acad. Sci. USA 109 2012 3143 3148
37. W. Wente, A.M. Efanov, M. Brenner, A. Kharitonenkov, A. Köster, G.E. Sandusky, S. Sewing, I. Treinies, H. Zitzer, and J. Gromada Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways Diabetes 55 2006 2470 2478
38. D.R. Whiting, L. Guariguata, C. Weil, and J. Shaw IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 Diabetes Res. Clin. Pract. 94 2011 311 321
39. J. Xu, D.J. Lloyd, C. Hale, S. Stanislaus, M. Chen, G. Sivits, S. Vonderfecht, R. Hecht, Y.S. Li, and R.A. Lindberg Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice Diabetes 58 2009 250 259
40. C. Zheng, C. Khoo, J. Furtado, and F.M. Sacks Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype Circulation 121 2010 1722 1734